Ventyx Biosciences, Inc. (VTYX): Price and Financial Metrics


Ventyx Biosciences, Inc. (VTYX): $34.91

-0.21 (-0.60%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add VTYX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

VTYX Stock Price Chart Interactive Chart >

Price chart for VTYX

VTYX Price/Volume Stats

Current price $34.91 52-week high $41.29
Prev. close $35.12 52-week low $9.50
Day low $34.42 Volume 840,779
Day high $37.28 Avg. volume 304,736
50-day MA $24.22 Dividend yield N/A
200-day MA $16.86 Market Cap 1.78B

Ventyx Biosciences, Inc. (VTYX) Company Bio


Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that has completed phase I clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases. In addition, the company develops CNS-penetrant NLRP3 inhibitors. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.


VTYX Latest News Stream


Event/Time News Detail
Loading, please wait...

VTYX Latest Social Stream


Loading social stream, please wait...

View Full VTYX Social Stream

Latest VTYX News From Around the Web

Below are the latest news stories about VENTYX BIOSCIENCES INC that investors may wish to consider to help them evaluate VTYX as an investment opportunity.

Ventyx Biosciences (VTYX) Gets a Buy from H.C. Wainwright

H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on Ventyx Biosciences (VTYX - Research Report) today and set a price target of $50.00. The company's shares opened today at $35.61.According to TipRanks, Bodnar is an analyst with an average return of -18.6% and a 20.59% success rate. Bodnar covers the Healthcare sector, focusing on stocks such as Imunon, Context Therapeutics, and Ventyx Biosciences.The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ventyx Biosciences with a $53.71 average price target, which is a 50.83% upside from current levels.

Jason Carr on TipRanks | September 29, 2022

10 Best-Performing Non-Energy Stocks of 2022

In this article, we discuss 10 best performing non-energy stocks of 2022. If you want to see more stocks in this selection, click 5 Best-Performing Non-Energy Stocks of 2022. On Friday, September 16, Wall Street concluded another one of its abysmal weeks in months, as investors reacted to a weak earnings indication from FedEx regarding […]

Yahoo | September 19, 2022

Ventyx Biosciences Announces $176.6 Million Private Placement of Common Stock

ENCINITAS, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, announced today that it has entered into a stock purchase agreement for the sale of 5,350,000 shares of its common stock at an offering price of $33.00 per share in a private placement to certain qualified institutional buyers

Yahoo | September 19, 2022

Why Ventyx Biosciences Zoomed Nearly 60% Higher This Week

One standout in a gloomy stock market this week was Ventyx Biosciences (NASDAQ: VTYX). According to data compiled by S&P Global Market Intelligence, the clinical-stage biotech's shares soared more than 58% higher during the period, thanks to the approval of a drug that hasn't actually been developed by the company. The treatment in question is Bristol Myers Squibb's deucravacitinib (brand name: Sotyktu), which was approved by the U.S. Food and Drug Administration (FDA) last Friday.

Yahoo | September 16, 2022

Bristol Myers Squibb Shakes Up Key Biotech Battleground

The FDA approval of Sotyktu for psoriasis has ignited and dampened prospects for smaller biotech stocks.

Yahoo | September 14, 2022

Read More 'VTYX' Stories Here

VTYX Price Returns

1-mo 71.13%
3-mo 176.19%
6-mo 159.55%
1-year N/A
3-year N/A
5-year N/A
YTD 75.78%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6033 seconds.